News Search Results
Apr 02, 2026, 06:00 ET AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
Europe, with planned expansion to Japan..About B-Cell MalignanciesB-cell malignancies — including non-Hodgkin lymphomas, multiple myeloma, and B-cell acute lymphoblastic leukemia (B-ALL) — account for the majority of blood cancers. Approximately 120,000 and 150,000 new cases are diagnosed
More news about: AvenCell Therapeutics, Inc.
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
120 target patients.CM336 (BCMA x CD3 bispecific antibody) : Data from the Phase II dose-expansion cohort in relapsed/refractory multiple myeloma (RRMM) showed an objective response rate (ORR) of 95.2% in the target dose group, with a ≥ complete response (≥CR) rate of 76.2%, a minimal residual
More news about: Keymed
Mar 26, 2026, 07:00 ET BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Mar 24, 2026, 07:01 ET Karyopharm Announces $30 Million Private Placement with RA Capital
Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).Forward-Looking StatementsThis press release contains
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
with VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 04:45 ET IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
China-developed CAR-T therapy as soon as possible."About Multiple Myeloma (MM)Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. According to Globocan data, the global incidence rate of multiple myeloma in 2022 was 1.8 per 100,000 population, with a 5-year prevalence
More news about: IASO Bio
Mar 23, 2026, 07:45 ET Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March
More news about: TuHURA Biosciences, Inc.
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights
More news about: BioLineRx Ltd.
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
® received approval for its third indication in the Mainland of China, bringing a new treatment option to patients with multiple myeloma (MM) who have received at least one prior therapy. Among the three approved indications of XPOVIO®, two
More news about: Antengene Corporation Limited
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry (IHC), Others), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Others), End-user, and Regional Analysis from 2026 – 2033
More news about: Persistence Market Research Pvt. Ltd.
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
positive pivotal Phase 2 iMMagine-1 data for its Arcellx-partnered CAR T-cell therapy anitocabtagene autoleucel in 4L+ relapsed or refractory multiple myeloma at the 2025 American Society of Hematology meeting, with two additional cancer therapy launches anticipated in 2026."In 2026, our potential
More news about: USA News Group
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
malignancies, bladder cancers and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Mar 16, 2026, 07:00 ET BioLineRx to Report 2025 Annual Results on March 23, 2026
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights
More news about: BioLineRx Ltd.
Mar 10, 2026, 08:42 ET Discuss Everything You Want to Know About Cancer with Experts at Community Education Series
Multiple Myeloma and Amyloidosis MDTs at Karmanos, and associate professor of Oncology at WSU, and Lara Sucheston-Campbell, Ph.D., professor of Oncology at WSU, will share what to expect after a multiple myeloma diagnosis, treatment options and clinical trials
More news about: Karmanos Cancer Institute
Mar 09, 2026, 16:23 ET Cell and Gene Therapy Manufacturing Market to Reach USD 146.2 Billion by 2032 Amid Rising Demand for Personalized Therapies, Viral Vector Capacity, and Automated Bioprocessing - Credence Research
next-generation cell therapy manufacturing facility in Pennsylvania focused on personalized cell therapies, including treatments targeting multiple myeloma.In February 2026, Cellipont Bioservices and Soter Bio announced a strategic collaboration to offer integrated U.S.-based
More news about: Credence Research Inc.
Mar 06, 2026, 08:00 ET U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.1"The newly approved TECVAYLI plus DARZALEX FASPRO treatment regimen, in which both drugs are administered subcutaneously, offers patients with relapsed or refractory multiple myeloma a new, effective
More news about: Halozyme Therapeutics, Inc.
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
product against B-cell maturation antigen (BCMA) approved by the NMPA of China for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent).CARsgen
More news about: CARsgen Therapeutics
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
www.DARZALEX.com.About Multiple MyelomaMultiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.8 In multiple myeloma, these plasma cells proliferate and spread rapidly and
More news about: Johnson & Johnson
Mar 05, 2026, 10:57 ET Tampa General Hospital Foundation Receives $10 Million to Innovate Cancer Research and Care
the ability to target cancer with immunotherapy," said Dr. Ivan Borrello, hematologist oncologist, physician-scientist and medical director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies program. "We are grateful and humbled by this wonderful gift, which will pave the pathway to new innovation
More news about: Tampa General Hospital
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
or refractory multiple myeloma. The study will evaluate cemsidomide in combination with dexamethasone, building on the compelling anti-myeloma activity observed in early-phase studies."Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated
More news about: Equity Insider
Mar 03, 2026, 14:36 ET Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
in specific leukemias and lymphomas and are expanding into multiple myeloma and additional hematologic indications. For instance, Novartis Pharmaceuticals' PHE885, a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma, uses the T-Charge platform to improve T-cell persistence and shorten
More news about: Credence Research Inc.
Mar 03, 2026, 09:00 ET Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
make the most of that potential for patients with multiple myeloma," said Daniel O'Day, Chairman and CEO of Gilead Sciences. "Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy."The acquisition
More news about: USA News Group
Mar 03, 2026, 08:01 ET Vibrant Emotional Health Names Laura Gilman Chief Development Officer Amid Growing Demand for Mental Health Care
strategies to support research innovation and patient-centered care. Previously, she served as Vice President of Events and Partnerships at the Multiple Myeloma Research Foundation (MMRF), overseeing more than 50 global fundraising events and generating over $10 million annually, while securing major corporate
More news about: Vibrant Emotional Health
Mar 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Mar 02, 2026, 10:32 ET Breckenridge launches Pomalidomide Capsules, strengthening its oncology portfolio
oncology generics portfolio. Pomalidomide Capsules, a thalidomide analogue, is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within
More news about: Breckenridge Pharmaceutical, Inc.